5 Key Takeaways

• 1

  The SALWEEN study showed that Vabysmo therapy significantly improved vision in patients with polypoidal choroidal vasculopathy.

• 2

  Patients treated with Vabysmo gained an average of 8.9 letters in best-corrected visual acuity after one year.

• 3

  More than half of the patients were able to extend treatment intervals to 20 weeks, reducing the treatment burden.

• 4

  The study demonstrated high rates of disease control, with 61% of patients achieving complete regression of lesions.

• 5

  The ongoing SALWEEN trial aims to further evaluate the efficacy, safety, and durability of Vabysmo beyond one year.